Edition:
India

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

2.90USD
20 May 2019
Change (% chg)

-- (--)
Prev Close
$2.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
320,917
52-wk High
$3.86
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Agenus Reports Q4 Loss Per Share Of $0.40
Thursday, 14 Mar 2019 

March 14 (Reuters) - Agenus Inc ::AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.40.Q4 REVENUE $6.5 MILLION.GILEAD COLLABORATION RESULTS IN CASH INFUSION OF $150 MILLION; FIRST MILESTONE PAYMENT OF $7.5 MILLION TRIGGERED.CTLA-4 & PD-1 TRIALS ARE ACCRUING FOR PLANNED BLA FILING AS EARLY AS 2020.NEXT-GEN CTLA-4 ADVANCING - EXPECT FIRST PATIENT TO BE DOSED THIS MONTH.FIRST YEAR REVENUES OF GSK'S SHINGRIX CONTAINING QS-21 EXCEED $1BN.ENDED 2018 WITH A CASH BALANCE OF $53 MILLION FOLLOWED BY $150 MILLION RECEIVED FROM GILEAD IN 2019.  Full Article

Gilead Sciences Reports 9.3 pct Passive Stake In Agenus Inc As Of Jan 23, 2019 – SEC Filing
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Agenus Inc ::GILEAD SCIENCES INC REPORTS 9.3 PERCENT PASSIVE STAKE IN AGENUS INC AS OF JAN 23, 2019 – SEC FILING.  Full Article

Selexis Expands Strategic Immuno-Oncology Alliance With Agenus
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Selexis SA::SELEXIS EXPANDS STRATEGIC IMMUNO-ONCOLOGY ALLIANCE WITH AGENUS.SELEXIS SA SAYS HAS SIGNED ADDITIONAL COMMERCIAL LICENSE AGREEMENTS WITH AGENUS.SELEXIS SA SAYS UNDER NEW LICENSE AGREEMENTS, AGENUS WILL LEVERAGE SELEXIS' MODULAR SURETECHNOLOGY PLATFORM FOR PRODUCTION OF ITS THERAPEUTIC PROTEINS.  Full Article

Agenus Says May Issue And Sell In Open Market Transactions And From Time To Time, Up To 30 Mln Shares Of Co's Common Stock
Thursday, 20 Dec 2018 

Dec 19 (Reuters) - Agenus Inc ::AGENUS INC - MAY ISSUE AND SELL IN OPEN MARKET TRANSACTIONS AND FROM TIME TO TIME, UP TO 30 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.AGENUS INC FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE AND SALE OF CO'S COMMON STOCK UNDER ATM SALES AGREEMENT WITH B. RILEY FBR, INC.  Full Article

Agenus Q2 Loss Per Share $0.24
Thursday, 9 Aug 2018 

Agenus Inc ::AGENUS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.24.Q2 REVENUE $16 MILLION.  Full Article

Agenus Inc Says Terminated Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & Co
Tuesday, 8 May 2018 

May 8 (Reuters) - Agenus Inc ::AGENUS INC - ON MAY 7 TERMINATED CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO.AGENUS SAYS 'AT-THE-MARKET' EQUITY OFFERING FACILITY UNDER SALES AGREEMENT NO LONGER AVAILABLE FOR USE - SEC FILING.  Full Article

Agenus Q1 Loss Per Share $0.53
Monday, 7 May 2018 

Agenus Inc ::AGENUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.53.Q1 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS WERE $52.3 MILLION AND $60.2 MILLION AT MARCH 31, 2018 AND DECEMBER 31, 2017 RESPECTIVELY.  Full Article

Agenus Inc Files For Sale Of Up 10 Mln Shares Of Common Stock By Selling Stockholders
Thursday, 25 Jan 2018 

Jan 24 (Reuters) - Agenus Inc ::AGENUS INC FILES FOR SALE OF UP 10 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Agenus Inc ::AGENUS ANNOUNCES COMBINATION CLINICAL TRIALS OF ITS ANTI-CTLA4 (AGEN1884) & ANTI-PD1 (AGEN2034).AGENUS INC - ANNOUNCED LAUNCH OF COMBINATION TRIAL WITH ITS PROPRIETARY ANTI-CTLA4 AND ANTI-PD1 ANTIBODIES.  Full Article

Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agenus Inc ::AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS.AGENUS INC - TRANSACTION IS COMPRISED OF $190 MILLION OF CASH PROCEEDS AT CLOSING PLUS UP TO $40 MILLION IN MILESTONE PAYMENTS.AGENUS INC - AGENUS WILL USE PART OF THE PROCEEDS TO REDEEM ITS ROYALTY BOND FROM OBERLAND, AMONG OTHERS.AGENUS INC - IN EVENT THAT CERTAIN SALES MILESTONES ARE NOT MET, AGENUS WILL OWE HCR APPROXIMATELY $26 MILLION IN 2021.  Full Article

Photo

Agenus shares soar after cancer therapy deal with Gilead

Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.